Who are Fluticasone furoate/umeclidinium/vilanterol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FF/UMEC/VI (100/31.25/25) mcg, FF/UMEC/VI (200/31.25/25) mcg.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fluticasone-furoate-umeclidinium-vilanterol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Fluticasone furoate/umeclidinium/vilanterol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fluticasone furoate/umeclidinium/vilanterol (Fluticasone furoate/umeclidinium/vilanterol) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-2 agonist combination. Area: Respiratory/Pulmonolog

marketed Inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-2 agonist combination Glucocorticoid receptor, M3 muscarinic receptor, beta-2 adrenergic receptor Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Fluticasone furoate/umeclidinium/vilanterol (Fluticasone furoate/umeclidinium/vilanterol) — GlaxoSmithKline. This triple-combination inhaler reduces airway inflammation and improves airflow by combining a corticosteroid, an anticholinergic, and a long-acting beta-2 agonist.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Fluticasone furoate/umeclidinium/vilanterol TARGET	Fluticasone furoate/umeclidinium/vilanterol	GlaxoSmithKline	marketed	Inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-2 agonist combination	Glucocorticoid receptor, M3 muscarinic receptor, beta-2 adrenergic receptor
FF/UMEC/VI (100/31.25/25) mcg	FF/UMEC/VI (100/31.25/25) mcg	GlaxoSmithKline	phase 3	Triple-combination inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-2 agonist	Glucocorticoid receptor, M3 muscarinic receptor, beta-2 adrenergic receptor
FF/UMEC/VI (200/31.25/25) mcg	FF/UMEC/VI (200/31.25/25) mcg	GlaxoSmithKline	phase 3	Triple combination inhaler (ICS/LAMA/LABA)	Glucocorticoid receptor, M3 muscarinic receptor, beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-2 agonist combination class)

GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fluticasone furoate/umeclidinium/vilanterol — Competitive Intelligence Brief. https://druglandscape.com/ci/fluticasone-furoate-umeclidinium-vilanterol. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab